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Hypertension, orthostatic hypotension, arterial insuﬃciency, and atherosclerosis are common disorders in the elderly that lead to
signiﬁcant morbidity and mortality. One common factor to these conditions is an age-related decline in vascular beta-adrenergic
receptor-mediated function and subsequent cAMP generation. Presently, there is no single cellular factor that can explain this age-
related decline, and thus, the primary cause of this homeostatic imbalance is yet to be identiﬁed. However, the etiology is clearly
associated with an age-related change in the ability of beta-adrenergic receptor to respond to agonist at the cellular level in the
vasculature. This paper will review what is presently understood regarding the molecular and biochemical basis of age-impaired
beta-adrenergic receptor-mediated signaling. A fundamental understanding of why β-AR-mediated vasorelaxation is impaired
with age will provide new insights and innovative strategies for the management of multiple clinical disorders.
1.Introduction
1.1. Clinical Relevance. Life expectancy has increased during
the past century, and this has led to a dramatic increase
in the aging population. The number of Americans over
65 is expected to double from the years 2000 to 2030: in
2000, there were 34.8 million over the age of 65 (12% of
the population), and in 2030, it is predicted that there will
be 70.3 million in this age group (representing 20% of
the population) [1]. This change in population dynamics
presents substantial medical issues, as aging is a primary
independent risk factor for development of cardiovascular
disorders. The fact that aging contributes to cardiovascular
morbidityisnotnovel.SirWilliamOsler(1849–1919),oneof
the founders of Johns Hopkins University Hospital, stated in
his textbook that, “Longevity is a vascular question...am a n
is only as old as his arteries.” From a strictly aging/vascular
perspective, numerous recent articles have described changes
in anatomical and histological properties with age (e.g., see
[2])as wellas biophysical alterations, suchas withchanges in
pulse wave velocity with age (as described in [3]). However,
one possibility to consider is that these aforementioned
changes are likely due to aging-mediated alterations in the
molecular and biochemical factors that determine vascular
tone.
Vascular tone is regulated by both the intimal (endothe-
lial) and medial (vascular smooth muscle) layers as well as
through interlayer interactions. Age-related changes in the
structure and function of each layer is well documented
[4, 5]. Smooth muscle cells represent the major arterial
cell population, and these cells highly express adrenergic
receptors that mediate smooth muscle tone. Thus, adren-
ergic receptors are important regulators of cardiovascular
physiology. Although all three beta adrenergic receptor
(β-AR) subtypes, β1, β2, and β3, are found in vascular
smooth muscle cells, the β2-AR subtype is by far the most
highly expressed [6]. Of speciﬁc relevance to this paper
is that the vascular β2-AR exhibits an age-related decline
in signaling with advancing age that leads to impaired
vasorelaxation. In contrast, the intrinsic ability for vascular
muscle contraction is generally maintained throughout the
aging process [7]. This change is important, because it may
allow for multiple age-associated clinical conditions such as2 International Journal of Hypertension
hypertension, arterial insuﬃciency, orthostatic hypotension,
and arteriosclerosis. The underlying change is hypothesized
to be a decrease in β-AR-stimulated cAMP production.
Therefore, conditions associated with altered cAMP produc-
tion are likely aﬀected. To this end, the β-AR is a target for
many medications prescribed to the elderly [8] and are used
to manage hypertension, angina, postmyocardial infarction
risk,congestiveheartfailure,glaucoma,tremor,arrhythmias,
and chronic obstructive pulmonary disorders [9].
1.2. Basic Science Relevance. Beta-AR-mediated signal trans-
duction pathways are well described, but new discoveries
continue to impart complexity (see [10] and following
sections). At present, no change in any one factor in the
β-AR signal cascade has been identiﬁed to fully explain
the impaired β-AR vascular function observed with aging.
Instead, the cause of the change is likely multifactorial.
This notion is supported due to intricate nature of β-
AR signaling and two biochemical ﬁndings: ﬁrst is that
expression of β2-AR does not change with age [11], and
secondly, although drugs that activate β-ARs do not elicit
complete vasorelaxation with advancing age, drugs that act
on proteins postreceptor in the signaling cascade do [12].
That is, the physiologic factors that mediate vasorelaxation
cannot completely dilate blood vessels with advancing age;
however, the molecular and cellular/anatomic machinery—
postreceptor—remains fully functional.
2. Contraction/RelaxationVascular
Pharmacodynamics
2.1. Mechanisms of Vascular Contraction/Relaxation. Vascu-
lar tone is physically established in the medial layer of
blood vessels, which is almost entirely composed of vascular
smooth muscle cells. Numerous agents (epinephrine, nore-
pinephrine, acetylcholine, angiotensin II, nitric oxide, etc.)
functionthroughtheircognatereceptorslocalizedatvascular
smooth muscle, and/or endothelial cells and inﬂuence an
elaborate network of signal transduction pathways that
yields homeostatic control [13]. The molecular mechanisms
regulating smooth muscle contraction and relaxation are
beyond the scope of this paper; however, excellent reviews
are found elsewhere [14, 15].
2.2. Vascular β-AR Signaling. In blood vessels, the β-AR
signal transduction cascade mediates smooth muscle vasore-
laxation. Activation of the β-AR stimulates the dissociation
of the G protein, Gαs, from the βγ subunit. The G protein βγ
subunit can also aﬀect various membrane and/or organelle
channels whose action can rapidly alter the ionic milieu
of the cell. After uncoupling from the β-AR, Gαsb e c o m e s
activated by exchanging GDP for GTP. The activated form of
Gαs triggers adenylyl cyclase to convert ATP into cAMP [16].
Two molecules of this second messenger bind one regulatory
subunit of protein kinase A (PKA). Structurally, PKA is
a tetrameric kinase made up of regulatory and catalytic
subunit dimers. Functionally, PKA is a multipurpose kinase
that controls numerous cellular events by phosphorylating
protein targets. PKA is distributed to multiple discrete intra-
cellular compartments via the function of A-kinase anchor-
ing proteins (AKAP) [17]. β-AR activation also initiates G
protein receptor kinase (GRK) function. GRKs are a family
of kinases that phosphorylate, β-ARs [18]. Phosphorylated
β-ARs are targets for still another group of proteins, the β-
arrestins that desensitize β-ARs and mediate internalization,
which leads to receptor recycling and/or degradation. In
addition, β-arrestins can serve as scaﬀolds and adaptors for
other kinases such as extracellular signal-regulated kinase
(ERK), Src, and Raf that regulate several cellular pathways
that result in the activation of MAP kinases [19].
Identifying a possible locus for the age-related decline in
β-AR function has proven elusive due to the complexity of
thiscascade.Threesubtypesoftheβ-AR(β1-AR,β2-AR,and
β3-AR) are found in vascular smooth muscle cells [20]. Also,
at least nine diﬀerent isoforms of adenylyl cyclase have been
identiﬁed [21, 22], along with at least six GRK [23], three
arrestin [24], and multiple types of AKAP [25]i s o f o r m sa r e
known to exist. Similarly, multiple Gαs-modifying proteins
are also known to alter β-AR signaling [26]. Therefore, to
understand the mechanism(s) of impaired β-AR function
with age, recent research has focused on proteins that
interact with the β-AR, directly or indirectly, that may
be critical for optimal receptor signaling. Investigations
on age-related changes in various modiﬁcations to the
β-AR, such as phosphorylation-mediated desensitization,
scaﬀolding proteins that form postreceptor signalosomes, or
proteins that directly interact and aﬀect β-AR function may
provide insight to explain the change.
3. Age-Related Changes inVascular Function
The initial observation of an aging eﬀect on vasorelaxation
was made in the early 1970s involving analysis of vascular
smooth muscle pharmacodynamics in general. Blood vessels
from 6-month-old animals relaxed 90% less to isoproterenol
as compared to blood vessels from 1-month-old animals
[27, 28]. To explain this physiologic change, biochemical
analysis found that both basal- and isoproterenol-mediated
cAMP synthesis signiﬁcantly declined in isolated aorta with
advancing age. This was in contrast to adenylyl cyclase and
phosphodiesterase activity that was essentially unaﬀected
by age. From these results, it was concluded that the
decreased ability of isoproterenol to elevate intracellular
cAMP concentration, and thus relax aortas from older rats
was predicated by an “upstream” change in the β-AR itself,
rather than a “downstream” change speciﬁc to adenylyl
cyclase [29]. From these initial observations, numerous
researchers have evaluated the aging vasculature in an
attempt to uncover the mechanism of this change in β-AR
function with age. As described above, the β-AR signaling
cascade is multifaceted, including numerous protein factors,
each of which exists with multiple subtypes. The following
is a discussion of what is currently known regarding the
mechanism of the age-related change in β-AR function,
organized in a sequential manner, starting upstream with
the β-AR itself and continuing through the cascade as we
currently understand it.International Journal of Hypertension 3
3.1. Beta-Adrenergic Receptors. Presently, three distinct sub-
types of the β-AR have been identiﬁed in mammals, (β1-
AR,β2-AR,andβ3-AR[20]:crystallinestructures(including
aﬀect of agonist occupancy) have recently been described
[30]. Most of the literature demonstrates that the primary β-
AR subtype in the vasculature is the β2-AR [31], but both
β1-AR and β3-AR are present and mediate vasorelaxation
[32]. The overall distribution, and relative proportion, of
eachβ-ARsubtypevariesacr ossvascularbeds[33,34].These
three β-AR subtypes work in concert to alter vascular tone
in a complementary manner, as they all couple to Gαsa n d
promote cAMP production [35].
The vascular adrenergic receptor subtypes behave dif-
ferently after exposure to agonist. Both β1-AR and β2-AR
desensitize with activation due to the function of GRKs,
PKA, as well as other kinases and/or factors [36, 37].
Interestingly, agonist exposure to the β2-AR also initiates
the transformation of its G protein-coupling selectivity from
Gαst oG αi[ 38]. This phenomenon has been documented
in the heart [39] and multiple cultured cell lines [40]. When
the β2-AR is linked to Gαi, one cellular event that occurs is
an inhibition of adenylyl cyclase activity that is manifested
as a reduction of intracellular cAMP concentration [41].
There are no data to suggest that β1-AR changes its Gα
protein subtype coupling preference. In contrast, the β3-
AR does not appear to undergo desensitization, as it lacks
regulatory phosphorylation sites for GRKs, PKA, or other
kinases [42]. This characteristic may allow for prolonged
signaling compared to β1-AR- and β2-AR-mediated eﬀects.
Although expression levels of the three adrenergic receptor
types is diﬀerential, with β2 being the most predominant
subtype, and β3 being the least expressed, patterns of
functioncouldbealteredwithpathology.Forinstance,under
maintained stimulation, β1-AR is predicted to desensitize,
β2-AR is predicted to desensitize and further inhibit cAMP
production through its linkage to Gαi[ 43], and β3-AR is
predicted to possibly represent a functional alternative for
cAMP production [6].
We have evaluated whether an agonist-mediated change
in β2-AR/G protein coupling observed in the heart could
explain the age-related change in vasorelaxation [12]. Using
pertussis toxin (pertussis toxin irreversibly ADP ribosylates
and inactivates Gαi) to block the coupling of activated
β2-AR to Gαi in aortae isolated from Fischer 344 rats
of increasing age, it was found that this treatment did
not alter the age-related decline in relaxation. However, a
population of β2-AR coupled to Gαi was found, as pertussis
toxin treatment improved β2-AR-mediated vasorelaxation
in aortae for all ages in equal proportion. Changes in
vascular β3-AR function with aging are unknown. However,
left ventricular function and age-related heart failure were
highly correlated with β3-AR expression in rats [44]. These
ﬁndings suggest that further investigation is warranted to
characterize AR subtype expression patterns and β3-AR
function throughout the vasculature.
Because the β2-AR is the most highly expressed subtype
in the vasculature, much interest is the ﬁnding that β2-
AR sensitivity substantially declines with age [45]. Results
foundthatinaorticpreparationsfrom1-month-oldanimals,
64% of the β-ARs were in the high aﬃnity state. This
compared to 40%, and 0% high aﬃnity β-ARs for 6- and
24-month-old animals, respectively. To explain these results,
age-related changes in the content of β2-AR bound to Gαs
was examined: β2A R : G αsc o m p l e x e sw e r ef o u n donly in
aortic preparations from 1-month-old animals. These data
strongly suggest that there is a substantial decline in high-
aﬃnity β2-AR with advancing age. This change did not
appear to be related to a decline in the presence of β-ARs
at the membrane (further conﬁrmed [11]) or caused by a
switch in G protein coupling as occurs in cardiac tissue [12].
Another interesting possibility to explain the age-related
decline in β2-AR signaling is the possibility that β-AR
can form hetero- and homodimers, and this could alter
signaling ﬁdelity. Mercier et al. [46] showed that β-ARs likely
exist as either β1-AR: β1-AR homodimers, or β1-AR:β2-
AR heterodimers, and they suggested that changes in the
overall cellular conﬁguration of monomers, heterodimers,
and homodimers could be altered by agonist as well as
disease state, and this ﬁnding was supported by Lavoie et al.
[47]. Also, β1-AR:β2-AR heterodimers have been shown to
exhibit distinct functional and pharmacological properties,
resulting in enhanced signaling eﬃciency in response to
agonist stimulation and optimizing β-adrenergic modu-
lation of contractility in cardiomyocytes [48]. However,
controversy exists as to whether β-AR dimerization occurs
in cardiovascular tissue. A report by Ianoul et al. [49] that
used higher-ﬁdelity imaging techniques suggested that β1-
AR and β2-AR may be localized in two diﬀerent popula-
tions of microdomains in cardiomyocytes, an observation
inconsistent with the existence dimers. Of additional interest
is a recent report by LaRocca et al. [50] that showed, also
in cardiomyocytes, that β2-AR form heterodimers with the
chemokine receptor type 4 (CXCR4) and this interaction
negativelyregulatedisoproterenol-mediatedβ2-ARsignaling
by altering β2-AR sensitivity. Following from these studies,
we evaluated whether CXCR4 activity modulation could
alter β-AR-meditated vasorelaxation. Using aortae isolated
from 2-month-old Fischer 344 rats, it appeared that CXCR4
activation inhibited, and CXCR4 blockade improved the
vasorelaxant eﬀect of isoproterenol (Figure 1). We also have
found that Fischer 344 aortic vascular smooth muscle
expresses CXCR4. Determination of age-related changes in
CXCR4-mediated alterations in β-AR-stimulated vasoreac-
tivity,CXCR4expression,andtheinteractionbetweenβ2-AR
and CXCR4 are underway.
3.2. G Proteins. The age-related change in β2-AR signaling
appears to caused by changes in receptor sensitivity, and
changes in G protein expression or function could manifest
this physiology. Interestingly, as with β-AR expression, Gαs
expression similarly remains unchanged [52]. However, its
functionappearstobeageimpaired,asdirectGαsactivation-
mediated cAMP production by was reduced in aortae
isolated from old rats [53]. Our lab further characterized
this observation by ﬁnding a marked decline in cholera
toxin catalyzed ADP ribosylation labeling of Gαs without a
decline in the expression [54], suggesting some age-related
alteration in G protein structure/function. We have also4 International Journal of Hypertension
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Figure 1:Vascularsmoothmuscleandchemokinereceptorsubtype
4 (CXCR4). (a) Aortae from 2-month-old animals (n = 5) were
isolated and mounted on an apparatus to measure vascular reac-
tivity as described [12]. Vessels were exposed to three treatments.
The control (CTRL) treatment was that vessels were contracted
with phenylephrine (PE) and allowed to stabilize (approximately 10
minutes) that was followed with relaxation stimulated by increasing
doses of isoproterenol (ISO). The stromal cell derived factor
(SDF1; ligand for the CXCR4 receptor also known as CXCL12)
treatmentwassimilarexceptthatafterthePE-mediatedcontraction
stabilized, 100ng/mL SDF1 was added. Following a 5-minute SDF1
incubation, relaxation was stimulated by increasing doses of ISO.
SDF1 did not alter the tone produced by PE alone. The AMD-
3100 (AMD; a CXCR4 speciﬁc antagonist) treatment occurred with
a4 5m i n u t e ,1 0μM AMD incubation preceding the PE-mediated
contraction and stabilization (10 minutes), which was followed by
relaxation stimulated by increasing doses of ISO. AMD treatment
did not eﬀect PE-mediated contraction as compared to CTRL.
Also conducted, but not shown, is that addition of AMD blocked
the eﬀect of SDF1 thereby implicating a direct eﬀect of CXCR4
on impairing β-AR-mediated vasorelaxation. Data are expressed as
percent of PE-induced contraction. The doses for AMD, and SDF1
were used as per LaRocca et al. [50]. (b) Aortic smooth muscle
medial layers were homogenized, and membrane-speciﬁc fractions
were prepared for western blotting as described [51]. Increasing
concentrations (5μg, 10μg, and 20μg; as determined with BCA
analysis)oftotalproteinextractswereloadedineachlane.Aspeciﬁc
antibody for CXCR4 (Abcam; Cambridge, Mass, USA) was used
to visualize expression of CXCR4 that is predicted to locate at
approximately 39 kilodaltons (kD). Shown also is a size-indicating
ladder (Ld).
found that cholera toxin-mediated relaxation in aortic rings
decreased with advancing age [7]. Further evidence that Gαs
function is altered with advancing age in the vasculature is
from a study where it was attempted to reverse age-related
declines in β-AR-mediated vasorelaxation by expressing a
constitutively activated mutant of Gαs( G αs-Q227L) into
aorta from 6-month-old Fisher 344 rats. In that study
[55], aorta that expressed Gαs-Q227L exhibited enhanced
isoproterenol-stimulatedvasorelaxation,andbothbasal-and
isoproterenol-stimulated cAMP production was increased.
Therefore, Gαs may undergo some age-related change that
inhibits its ability to become activated via the action of an
agonist-occupied receptor. In support of a functional change
in Gαs with age is the identiﬁcation of a regulator of G
protein signaling (RGS)/GTPase activating protein (GAP)
that functions on Gαs[ 26] called RGS-PX1. Age-related
enhanced RGS-PX1 activity could impair β-AR signaling
without changes in β-AR or Gαs expression as agonist
exposure would not initiate vasorelaxation as Gαs signaling
would be quenched due to the high RGS/GAP activity of
RGS-PX1. At present, RGS-PX1 has not been evaluated
within an aging paradigm. In total, the decline in β-AR-
mediated vasorelaxation and cAMP accumulation observed
in old vessels could be caused by a change in the function but
not expression of Gαs.
Another possible explanation for the decline in β-AR-
mediated signaling could be an increase in Gαi function, as
this G protein subunit inhibits adenylyl cyclase activity and
thus cAMP production. Also, the β2-AR, the predominant
receptor species in vascular smooth muscle, has been shown
in cardiomyocytes to rapidly link to Gαi after agonist
activation, and it is PKA-phosphorylated [38]. We actually
found a slight decline in pertussis toxin labeling of Gαiw i t h
age [54]. Also, a 30% decrease in Gαi1&2 protein content
between 6- and 24-month-old aortic preparations has been
documented [52]. Age-related changes in Gβγ could also
aﬀect β-AR-mediated signaling. Gβγ has been shown to
either stimulate or inhibit adenylyl cyclase activity in the
presence of activated Gαs[ 56]. Gβγ also aﬀects numerous
plasma and organelle membrane-localized ion channels,
thereby aﬀecting the net polarity and potential for tonal
changes of vascular smooth muscle [57]. However, we have
found no age-related changes in the expression of Gβγ
subunit [54].
3.3. Adenylyl Cyclase, Protein Kinase A, cAMP, and Phospho-
diesterases. As discussed, the fundamental change in blood
vessels from older animals is a pronounced inability to relax
to β-AR stimulation. This decline is directly correlated to an
inability to synthesize appreciable concentrations of cAMP.
However, old vessels do maintain the ability to relax entirely,
as acetylcholine-, forskolin-, and nitrate-mediated vasore-
laxation is complete [58]. Therefore, a probable protein
candidate for the impairment is Gαs (as discussed previous)
or G protein receptor kinase (see following). The classical
eﬀectorofGαs is adenylyl cyclase. Forskolin directly activates
adenylyl cyclase, and thus stimulates cAMP production.
Because forskolin stimulates blood vessels from young andInternational Journal of Hypertension 5
old animals to relax completely, and to accumulate cAMP
equally, it is generally thought that adenylyl cyclase function
does not change with advancing age. Our results further
support that adenylyl cyclase activity is maintained across
aging [59]. However, the adenylyl cyclase family contains
nine diﬀerent isoforms, each with discrete tissue distribution
[60].Perhapsmoreimportantly,eachisoformisdiﬀerentially
regulated by various factors. For instance, calcium (at
relevant intracellular concentrations) stimulates adenylyl
cyclase subtype-1, and subtype-8 but inhibits subtype-3 and
subtype-9. Interestingly, Zhang et al. have demonstrated
that the predominant adenylyl cyclase isoforms in vascular
smooth muscle are of the calcium-sensitive variety [61].
Therefore, a possible explanation for impaired receptor-
mediated-cAMP production is not with the cyclase itself,
but rather the interaction between cyclase and another,
critical and age-aﬀected, cellular factor that could regulate
intracellular calcium sequestration.
Another line of reasoning would be that adenylyl cyclase
activity is unchanged across age, but cAMP processing is
altered. Therefore, changes in physiology could be due to
age-related changes in the processing and degradation of
cAMP through phosphodiesterases. We have determined
that there are no age-related changes in general phosphodi-
esterase inhibitor-mediated vasorelaxation using 3-isobutyl-
1-methylxanthine (IBMX), a nonspeciﬁc phosphodiesterase
subtype inhibitory agent [62]. However, others [63]f o u n d
that using a low dose of IBMX caused impaired cAMP
accumulation in blood vessel preparation from older rats.
The role of phosphodiesterases in mediating age-related
changes in cAMP concentration is presently underevaluated.
There are multiple phosphodiesterase subtypes, each that
may have diﬀerential expression or activity [64]. Also, only
recently have drugs speciﬁc to individual isoforms have
becomeavailable.Tothatend,ithasrecentlybeenshownthat
the vasodilator pathway associated with phosphodiesterase
III is likely unchanged with aging in humans [65].
3.4.GProteinReceptorKinasesandArrestins. β-ARdesensiti-
zation is initiated by phosphorylation of the receptor, which
is followed by its uncoupling from its signaling cascade.
The kinases PKA, GRK, and others phosphorylate β-ARs
[37]. Phosphorylated β-ARs are targets for another family
of proteins that mediate uncoupling/desensitization, the
arrestins [24]. Therefore, arrestins function in concert with
GRKs to attenuate intracellular signaling [66, 67]. To date,
six diﬀerent GRKs have been identiﬁed. Of interest, GRK-2,
GRK-3,andGRK-5(GRK-2andGRK-3arealsoknownasβ-
AR kinases: β-ARK-1 and β-ARK-2, resp.) target β-ARs and
are highly expressed in the cardiovascular system [23].
Evidence shows that GRKs are important regulators of
pathology in humans [68]. Signiﬁcant increases in GRK
activity and expression have been observed in ventricles of
failing human hearts [69]. The progression of Alzheimer’s
disease has also been associated with enhanced GRK func-
tion in ﬁbroblasts taken from human skin [70]. Relating
speciﬁcally to GRK function and the vasculature, cultured
vascular smooth muscle cells have been shown to express
GRK-2 both within the cytoplasm and at the membrane
[71], and a transgenic mouse that overexpressed GRK-2 in
a vascular-speciﬁc manner has been developed [72]. These
mice exhibited attenuated β-AR-mediated cAMP production
and vasorelaxation. Also, overexpression caused elevations
in resting blood pressure and was accompanied by an
increaseinvascularthickening, suggestingadeclineincAMP
generation.
An age-related change in GRK activity or expression
in vascular tissue would implicate GRKs in the age-related
decline in β-AR mediated vasorelaxation. Only a few studies
have been performed to assess age-related changes in GRKs.
N oc h a n g e si nG R Ka c t i v i t yo rG R K - 2a n d5e x p r e s s i o nw e r e
observed in lymphocytes of aged humans [73]. However,
expression of soluble GRK-2 increased with maturation
in thoracic aortic preparations from Fischer 344/Brown
Norwayrats[11].Wehavealsoexaminedage-relatedchanges
in GRKs [51]. In aorta from aged Fischer 344 rats, total GRK
activity increased nearly 2.1-fold. In the soluble (cytosolic)
fraction, GRK-2 expression increased nearly 3.6-fold, GRK-3
expression increased approximately 3.8-fold, and β-arrestin
expression increased approximately 1.6-fold. In the mem-
brane fraction, GRK-2 expression increased approximately
1.5-fold, GRK-3 expression increased nearly 2.1-fold, while
there was not an age-related change in the expression of
GRK-5. These data suggest that a critical feature of age-
related impaired β-AR signaling may be imparted through
an increase in total pool of GRK that could be explained
by either increased expression, or decreased degradation
[74]. This increased pool could allow for enhanced targeting
of these receptor kinases to the membrane, and hence the
β-AR. Whether β-ARs from aged vessels have increased
phosphorylated residues, and thus enhanced desensitization
isyettobeestablished.Also,themechanismfortheenhanced
expression of GRKs with advancing age is likewise yet to be
explained but is an active interest of our lab.
3.5. Scaﬀolding. β-AR signaling depends on the interac-
tion between numerous proteins. Therefore, β-AR-mediated
function requires appropriate localization (cytoplasmic ver-
susmembrane)andorganization(toalloweﬃcientandrapid
interaction with one another) of these proteins. Therefore,
recent research has focused on “scaﬀolding proteins,” which
are intracellular proteins that compartmentalize multiple
related signaling molecules to speciﬁc intracellular domains.
This theory has replaced the classical “random collision-
coupling theory” of signal transduction [75]. The β-AR
signaling cascade is anchored within the plasma membrane
by the scaﬀolding protein caveolin [76]. β2-ARs [77, 78],
numerous G-proteins (including Gαs) [79, 80], adenylyl
cyclase (numerous isoforms) [80–82], and GRKs 2, 3, and
5[ 83] all localize in caveolin-rich domains of the cell
membrane.
Age-related changes in caveolin have recently been dem-
onstrated revealing tissue-speciﬁc changes in expression
[84]. Also, our results with Fischer 344 rat aortic tissue show
that the expression of caveolin-1 decreases with advancing
age [85]. An age-related change in caveolin expression could6 International Journal of Hypertension
easily alter the milieu of proteins within a β-AR signaling
pocket, and thereby alter signaling. Indeed, Carman et
al. [83] found that GRK activity is inhibited when GRK
is bound to caveolin-1. Our lab has shown that with
advancing age, the interaction between caveolin-1 and GRK2
substantially declines [85]. Therefore, both the scaﬀolding
and protein activity-modulating functions of caveolin may
be compromised with advancing age in the vasculature.
Otherreportsimplicatecaveolinasaregulatorofvascular
function [86]. Razani and Lisanti [87], and Drab et al.
[88] produced caveolin-1 null mice and found that these
animals exhibited impaired aortic steady-state maximal
tension induced by phenylephrine (an α-AR agonist). Also,
acetylcholine-mediated (nitric oxide-dependent) vasorelax-
ation was similarly altered in null animals. Finally, caveolin-
1 null mice displayed hyperproliferation in certain cell
types, suggesting (but not documented) a decline in cAMP
production. Changes in β-AR-, cAMP-, or age-mediated
eﬀects in the caveolin-1-null mice have yet to be evaluated.
However, these data from transgenic animals clearly indicate
thatcaveolinisanimportantmodulatorofvascularfunction.
3.6. Receptor Cross-Talk and Ion Channels. Ap o t e n t i a l l y
interesting phenomenon observed in molecular signaling is
receptor cross-talk events. Cross-talk between Gαq-linked
receptors and β-ARs have been observed. Activation of PKC
by Gαq-linked-agonists directed GRKs to the membrane,
enhancing β-AR phosphorylation and desensitization [89].
Also, it has been shown that GRK-2 is more eﬀective
at desensitizing β-ARs after its activation by PKC [90].
Finally, antisense technologies have been used to knockout
PKC expression and function; these studies determined
that this manipulation produced enhanced β-AR agonist-
induced desensitization rather than the expected attenuation
result. In addition, these authors subsequently found that
this eﬀect was linked to phosphatase activity [91]. These
ﬁndings suggest that PKC might also be involved with β-
AR resensitization through interaction with a phosphatase.
Therefore, phosphorylation/dephosphorylation and desen-
sitization/resensitization of β-ARs can be induced from a
number of stimuli including angiotensin II.
Intermsofvascularβ-ARbeingalteredbyreceptorcross-
talk are in vitro studies showing that angiotensin II enhanced
β-AR-mediatedcAMPproductioninculturedaorticvascular
smooth muscle cells [61, 92, 93]a sw e l la si np r e g l o m e r u l a r
microvascular smooth muscle cells [94, 95]. In terms of
vasorelaxation being aﬀected was a study that found that
angiotensin II can enhance cAMP-mediated vasorelaxation
via angiotensin II-type 1-receptors (AT1)[ 96]. We examined
the interaction among aging, β-AR-mediated vasorelaxation,
and angiotensin II [62]. Our results showed that this eﬀect
of angiotensin II on agonist-mediated vasorelaxation was
limited to young (6-week-old) or adult (6-month-old) rats,
wasabsentinaged(12-and24-month-old) animals,andwas
mediated by angiotensin II-type 1 receptors. Angiotensin II
appearedtoamplifyvasorelaxationinaortafrom6-weekand
6-month-oldanimalsviaenhancedproductionofcAMP.The
mechanisms involved with angiotensin II enhanced, β-AR-
mediated signaling are unknown but may involve adenylyl
cyclase, Gαs, or calcineurin. Further study may show that
aging may eﬀect a factor common to both angiotensin II and
β-AR signaling pathways or that aging may impair cross-talk
between these two receptor pathways.
A ﬁnal interesting aspect of age-related changes in β-AR-
mediated signaling is understanding the role of various ion
channels;itiswellunderstoodthatthefunctionofnumerous
ion channels is responsible for determining membrane
potential [97]. The eﬀect of isoproterenol on the ionic
milieu of aortic vascular smooth muscle cells was charac-
terized [98]. Results determined that isoproterenol func-
tioned by inducing hyperpolarization via activating ATP-
sensitive potassium channels (KATP). They also determined
that the isoproterenol/KATP-mediated hyperpolarization was
impaired in smooth muscle cells from older rats. However,
theeﬀectofdirectactivationofKATP wasunchangedbetween
youngandoldgroups.Therefore,theirdataﬁtwellwithwhat
has been previously known about the age-related changes
in β-AR signaling—the alteration appears to be localized
proximal to adenylyl cyclase and may involve changes in the
β-AR itself or in its ability to couple to other regulatory
molecules.
3.7. Endothelium-Localized β-AR/VSM Interactions. Ac o n -
troversial topic is the endothelium-mediated eﬀect on the
age-related change in β-AR function. It is clear that age-
related changes in the endothelium occur [99], and there are
endothelium-localized β-AR [100]. It is also well accepted
that removal of endothelium reduces the eﬀect of isopro-
terenol on vasorelaxation in a variety of isolated arteries
and veins from diﬀerent species, including humans [100].
Data show that endothelial cells have binding sites for β-
AR ligands [101] and that isoproterenol increases nitric
oxide synthase activity in these cells. Compatible with these
ﬁndings is that inhibition of nitric oxide synthase modestly
decreased relaxation to β-AR agonists [102]. Therefore,
endothelium- and vascular smooth muscle-mediated func-
tion may be additive in that β-AR-mediated vasorelaxation
appears to be induced via both nitric oxide-mediated path-
ways (endothelial), and cAMP-mediated pathways (vascular
smooth muscle) [103].
In terms of aging, β-AR vasorelaxation is initiated in
both endothelial and vascular smooth muscle cells. However,
[104] found that the endothelial component did not change
with age, whereas the vascular smooth muscle compo-
nent did. They did identify an age-speciﬁc, endothelium-
dependent eﬀect in that vascular tone appeared to be
mediated through an endothelium-derived hyperpolarizing
factor (tetraethylammonium-sensitive K+ channels) that
was increased with advancing age. Age-related changes
in membrane polarization are also discussed previously
where KATP-mediated hyperpolarization was found to be
impaired in vascular smooth muscle cells from older rats
[98]. Our lab has also produced data in support of a role
for changes in polarization in mediating the age-related
change in β-AR-mediated vasorelaxation. When comparingInternational Journal of Hypertension 7
the eﬀect of age on isoproterenol-mediated vasorelaxation
on phenylephrine- versus KCl-contracted aorta, vessels con-
tracted with phenylephrine relaxed to a substantially higher
degree that those contracted with KCl, although the age-
eﬀect was maintained [7]. One interpretation of this result
is that with advancing age, isoproterenol-mediated signaling
pathways involve an increased role for K+ channels. Further
support that the aging change in β-AR signaling is vas-
cular smooth muscle-, rather than endothelium-dependent
is that other agents that initiate vasorelaxation through
vascular smooth muscle localized G protein-coupled recep-
tors (adenosine, parathyroid hormone) also show impaired
vasorelaxationwithage[105,106].Therefore,theage-related
c h a n g ei sl i k e l yd u et oaf a c t o rc o m m o nt oa l lv a s c u l a r
smooth muscle-localized G protein-coupled receptors, such
as GRK (see above discussion), while a nonage-related
endothelial dependent component contributes to β-AR-
stimulated vasorelaxation in general.
4.SummaryandPerspectives
Hypertension,orthostatichypotension,arterialinsuﬃciency,
atherosclerosis, and restenosis are common disorders in
the elderly that lead to signiﬁcant morbidity and mortal-
ity. These clinically signiﬁcant conditions all may have a
common feature in that they are associated with and age-
related change in β-AR signaling. Impaired β-AR-mediated
vasorelaxation with age is observed throughout species
a n da r t e r i a lb e d s ,a n di na g e dv a s c u l a rt i s s u e ,β-ARs are
desensitized. One cellular process that changes with age
that modulates β-AR sensitivity is phosphorylation by GRK-
2. But, there are multiple other protein factors that may
modulate β-AR function with aging. Similarly, there are
multiple factors that may modulate GRK function [107].
Therefore, the overall complexity of the molecular pathways
creates diﬃculties in isolating a single therapeutic target.
Regardless, a large and growing segment of the general
population are age 65 or older, and this percentage will
continue to rise. Optimal care of this population is a priority
for clinicians, and better understanding of this age-related
change in the vasculature will allow for innovative strategies
for the management of multiple disorders. Findings will be
applicable to other tissues and disease states where β-AR
signaling is altered (such as in the kidney and liver [108],
heart [109], lung [110], and brain [111].
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